The DLG2 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the DLG2 gene, which encodes the synaptic scaffold protein discs large MAGUK scaffold protein 2. This heterogeneous pool provides a robust loss-of-function model, minimizing clonal artifacts and enabling reliable study of DLG2-dependent processes.
The HAP1 cell line is a near-haploid, adherent fibroblast-like line derived from the chronic myeloid leukemia KBM-7. Its near-haploid genome simplifies CRISPR editing, requiring disruption of a single allele, and facilitates genome-wide knockout screens. HAP1 cells possess a hematopoietic progenitor background, rapid proliferation, and ease of handling, making them ideal for biochemical assays, imaging, and high-throughput applications.
DLG2, a MAGUK family scaffold, organizes the postsynaptic density at excitatory synapses by clustering NMDA receptor subunits and Kv1.4/Kv4.2 potassium channels. It interacts with synaptic scaffolds DLG4 (PSD-95), Shank, and Homer to coordinate receptor localization and synaptic plasticity. Upstream, DLG2 is regulated by BDNF/TrkB signaling, neuronal activity, and transcription factors SP1 and CREB. Downstream, it promotes NMDA receptor clustering and potassium channel localization, while also interfacing with the Wnt pathway, thereby modulating synaptic strength and connectivity.
Disruption of DLG2 in HAP1 cells provides a unique, simplified system to dissect the molecular mechanisms of synaptic scaffold assembly in a non-neuronal, biochemically tractable context. This knockout model enables the study of DLG2??s role in protein?Cprotein interactions, cell adhesion, and signal transduction independent of the complex neuronal environment. HAP1 cells further permit robust assessment of DLG2-dependent recruitment and stabilization of its binding partners, offering a versatile platform to probe fundamental aspects of synaptic protein organization relevant to neuropsychiatric diseases.
Key applications include co-immunoprecipitation and western blotting for mapping interaction networks, immunofluorescence for protein localization, and cell adhesion assays. The polyclonal cells are also well-suited for drug screening targeting synaptic defects in schizophrenia, autism, and epilepsy, and for electrophysiological studies when paired with recombinant systems. For further product information, please contact Ascent Research.
